A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Phase of Trial: Phase III
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Ixekizumab (Primary)
- Indications Spondylarthritis
- Focus Registrational; Therapeutic Use
- Acronyms COAST-X
- Sponsors Eli Lilly
- 01 Aug 2017 Planned number of patients changed from 300 to 305.
- 01 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
- 27 Jul 2017 Planned End Date changed from 1 Jul 2018 to 1 Feb 2019.